There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Precision BioSciences (DTIL – Research Report) and Adicet Bio (ACET – Research Report) with bullish sentiments.
Precision BioSciences (DTIL)
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Precision BioSciences, with a price target of $60.00. The company’s shares closed last Wednesday at $12.12.
According to TipRanks.com, Trucchio is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Precision BioSciences has an analyst consensus of Strong Buy, with a price target consensus of $34.60, which is a 190.3% upside from current levels. In a report issued on April 30, Guggenheim also initiated coverage with a Buy rating on the stock with a $19.00 price target.
See the top stocks recommended by analysts >>
Adicet Bio (ACET)
In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on Adicet Bio, with a price target of $10.00. The company’s shares closed last Wednesday at $1.41, close to its 52-week low of $1.10.
According to TipRanks.com, White has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Adicet Bio has an analyst consensus of Strong Buy, with a price target consensus of $9.20, a 552.5% upside from current levels. In a report issued on May 13, JonesTrading also maintained a Buy rating on the stock with a $6.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DTIL:
- Precision BioSciences reports Q1 EPS $1.70, consensus ($1.91)
- DTIL Upcoming Earnings Report: What to Expect?
- Precision BioSciences partner receives fast track designation for ECUR-506
- Precision BioSciences initiated with a Buy at Guggenheim
- Precision BioSciences Faces Partnership Termination, Eyes Future
